Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.49 |
| ▸ | DHODH | Q02127 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16334337 | 0.88 | FFAR4 (0.47) | FFAR4DHODHFFAR1KAT6AENPP2 | |
| SCHEMBL16334437 | 0.85 | FFAR4 (0.54) | FFAR4DHODHFFAR1ENPP2 | |
| SCHEMBL16334426 | 0.82 | FFAR4 (0.56) | FFAR4DHODHFFAR1ENPP2SLC16A3 | |
| SCHEMBL16334862 | 0.82 | FFAR4 (0.51) | FFAR4DHODHFFAR1KAT6AENPP2 | |
| SCHEMBL1336643 | 0.77 | FFAR4 (0.51) | FFAR4DHODHFFAR1KAT6AENPP2 | |
| SCHEMBL16334746 | 0.76 | FFAR4 (0.56) | FFAR4DHODHFFAR1KAT6AENPP2 | |
| SCHEMBL28054784 | 0.75 | SLC6A2 (0.49) | FFAR4DHODHFFAR1KAT6AENPP2 | |
| SCHEMBL16334327 | 0.73 | FFAR4 (0.47) | FFAR4DHODHFFAR1ENPP2 | |
| SCHEMBL1336585 | 0.72 | FFAR4 (0.47) | FFAR4DHODHFFAR1KAT6APTGS1 | |
| SCHEMBL1337675 | 0.71 | DHODH (0.49) | FFAR4DHODHENPP2SLC16A3SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105392777-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2020-09-22 | — | — | CN | disclosed |
| EP-3013796-B9 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2020-07-01 | — | — | EP | disclosed |
| EP-3628661-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEM, LTD. (KR) | 2020-04-01 | — | — | EP | disclosed |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | LG CHEM, LTD. (KR) | 2019-03-05 | — | — | US | disclosed |
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2016-06-16 | — | — | US | disclosed |
| EP-3013796-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG Life Sciences Ltd. (KR) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014209034-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | GPR119, GLP1R, GIPR | FFAR4 16/4885DHODH 4532/4885FFAR1 8/4885 |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | GPR119, GLP1R, GIPR | FFAR4 16/4885DHODH 4532/4885FFAR1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.